Product Description
An inhibitor of spleen tyrosine kinase (syk), with potential anti-inflammatory, immunomodulating, and antineoplastic activities. (Sourced from: https://www.mycancergenome.org/content/drugs/mivavotinib/)
Mechanisms of Action: SYK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Calithera Biosciences
Company Location: Western America
Company CEO: Susan M. Molineaux
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acute Myeloid Leukemia|Diffuse Large B-Cell Lymphoma
Phase 1: Marginal Zone Lymphoma|Lymphoma|Lymphoma, Non-Hodgkin|Breast Cancer|Follicular Lymphoma|Head and Neck Cancer|Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Diffuse Large B-Cell Lymphoma|T-Cell Lymphoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03756818 |
NCI-2018-02665 | P1 |
Completed |
Ovarian Cancer |
2023-02-23 |
2023-03-01 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT03772288 |
C34015 | P1 |
Withdrawn |
Lymphoma, Non-Hodgkin |
2021-11-10 |
12% |
2023-02-09 |
Primary Endpoints|Treatments |
NCT03357627 |
C34008 | P1 |
Completed |
Follicular Lymphoma|Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin |
2021-08-03 |
41% |
2023-02-09 |
Primary Endpoints|Treatments |
NCT02000934 |
C34001 | P1 |
Completed |
Lymphoma |
2021-06-29 |
48% |
2023-02-09 |
Primary Endpoints|Treatments |
NCT03742258 |
NU 18H02 | P1 |
Completed |
T-Cell Lymphoma|Diffuse Large B-Cell Lymphoma |
2021-03-12 |
2025-08-27 |
Primary Endpoints|Treatments |
|
JapicCTI-173679 |
JapicCTI-173679 | P1 |
Unknown |
Marginal Zone Lymphoma|Follicular Lymphoma|Lymphoma, Non-Hodgkin |
2020-08-17 |
|||
NCT03238651 |
C34007 | P1 |
Terminated |
Follicular Lymphoma|Lymphoma, Non-Hodgkin|Marginal Zone Lymphoma |
2020-08-17 |
77% |
2023-02-09 |
Primary Endpoints|Treatments |
NCT02954406 |
C34005 | P1 |
Terminated |
Lymphoma, Non-Hodgkin |
2020-07-27 |
64% |
2022-02-19 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT03338881 |
C34010 | P1 |
Withdrawn |
Lymphoma |
2019-05-01 |
49% |
2023-02-09 |
Primary Endpoints|Treatments |
NCT03359733 |
C34009 | P1 |
Withdrawn |
Lymphoma |
2019-01-14 |
50% |
2023-02-09 |
|
NCT02834247 |
C34003 | P1 |
Terminated |
Non-Small-Cell Lung Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Breast Cancer |
2018-11-30 |
36% |
2023-02-09 |
|
NCT05319028 |
CX-659-401 | P2 |
Terminated |
Diffuse Large B-Cell Lymphoma |
2023-02-24 |
46% |
2023-04-05 |
Primary Endpoints |
NCT04079738 |
BTCRC-HEM17-092 | P2 |
Terminated |
Acute Myeloid Leukemia |
2021-09-22 |
20% |
2024-06-06 |
|
NCT03123393 |
C34004 | P2 |
Terminated |
Diffuse Large B-Cell Lymphoma |
2019-12-17 |
46% |
2023-02-09 |
|
2016-003716-12 |
2016-003716-12 | P2 |
Completed |
Diffuse Large B-Cell Lymphoma |
2019-12-17 |
46% |
2022-03-13 |
Treatments |
NCT02323113 |
C34002 | P2 |
Terminated |
Acute Myeloid Leukemia |
2018-06-08 |
41% |
2023-02-09 |
Primary Endpoints|Treatments |